Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CYW 628

Next Previous
Drug Profile

CYW 628

Alternative Names: CYW-628; CYWC-628

Latest Information Update: 07 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FibroBiologics
  • Class Fibroblast cell therapies
  • Mechanism of Action Fibroblast replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Diabetic foot ulcer
  • Preclinical Burns

Most Recent Events

  • 22 Jun 2026 The United States Patent and Trademark Office issues a Notice of Allowance for use of CYW 628 in Wound Healing in USA
  • 03 Jun 2026 Phase-I/II clinical trials in Diabetic foot ulcer (Treatment experienced) in Australia (Topical) (NCT07096934)
  • 05 May 2026 Pharmacodynamics data from a preclinical study in Burn wounds released by FibroBiologics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top